Propanc Biopharma financials
$0.5123−3.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$3.5M | -$6.4M | -$3.7M | -$4.7M |
| Net income | -$4.6M | -$6.4M | -$4.0M | -$4.8M |
| Net margin | — | — | — | — |
| Diluted EPS | — | $-0.28 | $-7.50 | $-9.75 |
| EBITDA | -$3.5M | -$6.4M | -$3.7M | -$4.7M |
| Operating cash flow | -$1.6M | -$1.1M | -$999.1K | -$1.9M |
| Free cash flow | -$1.6M | -$1.1M | -$1.0M | -$1.9M |
| Diluted shares | — | 22.4M | 0.5M | 0.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $832.0K | $443.7K | $561.2K | $602.7K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $643.5K | $760.5K | $782.9K |
| Total assets | $12.8M | $14.3M | $15.1M | $18.0M |
| Total liabilities | $3.4M | $3.5M | $3.7M | $3.6M |
| Shareholders' equity | $9.4M | $9.8M | $10.5M | $14.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology